CT-95 in Advanced Cancers Associated With Mesothelin Expression

This study tests CT-95, a new investigational cancer drug that targets mesothelin — a protein found on the surface of several cancer types — in people with advanced cancers that express this protein (such as mesothelioma, ovarian cancer, or pancreatic cancer). **You may be eligible if...** - You are in good health (ECOG 0–1) - You have confirmed advanced cancer that expresses the mesothelin protein - You have evaluable or measurable disease on imaging - Your organ function is adequate **You may NOT be eligible if...** - You have an uncontrolled serious infection or medical condition that would prevent safe participation - You have previously received a mesothelin-targeted CAR-T therapy or CD3-targeted treatment - You are currently enrolled in another clinical trial - You have cancer spreading along the lining of the brain or spinal cord (leptomeningeal disease) Talk to your doctor to see if this trial is right for you.